期刊文献+

补肾强脊颗粒治疗强直性脊柱炎疗效与安全性评价 被引量:12

Clinical Study on Effect and Safety of Bushen Qiangji Granule in Treating Ankylosing Spondylitis Patients
下载PDF
导出
摘要 目的评价补肾强脊颗粒治疗强直性脊柱炎(AS)肾虚血瘀证的疗效与安全性。方法采用随机、对照、单盲前瞻性研究,将68例AS肾虚血瘀证患者随机分为中药组和中西医结合组,中药组予以补肾强脊颗粒治疗,中西医结合组予以补肾强脊颗粒联合柳氮磺胺吡啶(SASP)治疗,连续用药6个月,选取治疗前、治疗1个月、治疗3个月、治疗6个月作为评价时点。结果中药组和中西医结合组总有效率分别为81·82%和86·82%,两组比较差异无显著性,但治疗第1个月,中药组和中西医结合组的总有效率分别为15·15%和27·59%,两组比较差异有显著性(P<0·01);两组患者Bath病情活动指数、Bath功能指数、疼痛、晨僵等临床症状均有明显的改善,Schober试验、胸廓活动度、指地距、ESR、CRP亦有改善;补肾强脊颗粒治疗AS疗效具有明显的时效性,随治疗时间延长,疗效逐渐增强(P<0·05或P<0·01);中西医结合组起效时间早于中药组。结论补肾强脊颗粒治疗AS临床疗效满意,安全性与依从性好,服用方便,具有广阔的应用前景和开发价值。 Objective To evaluate the efficacy and safety of Bushen Qiangji Granule (BQG) in treating ankylosing spondylitis (AS) patients with Sben-deficiency and blood-stasis syndrome. Methods A randomized controlled and single-blinded prospective clinical trial was carried out on 68 patients, who were randomly as- signed into the BQG group treated with BQG alone and the combined treated (CT) group treated with BQG and sulfasalazine, six-month medication was successively applied to both groups. The therapeutic effects were evaluated before treatment and at the end of the 1st, 3rd and 6th month of the treatment. Results The total effective rate was 81.82% in the BQG group and 86.82% in the CT group after 6 months of treatment, showing no significant difference between the two groups, but that after 1 months of treatment in the BQG group was lower than that in the combined group ( 15.15 % vs 27.59 % , P 〈 0.01). Bath AS disease activity index (BASDAI), Bath AS function index (BASFI), and clinical symptoms such as ache and morning stiffness, as well as indexes of Scbober test, activity of thoracic cage, finger-ground distance, erytbrocyte sedimentation rate (ESR) and Creactive protein (CRP) in both groups were improved remarkably. BQG showed a time-dependant effect, the therapeutic effect intensified as the time went by (P〈0.05 or P〈0.01). Moreover, the effect initiating time was earlier in the CT group than that in the BQG group. Conclusion BQG has satisfactory efficacy, good safety and compliance, and is convenient for administering, therefore, it has broad applying prospect with high exploiting value.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2006年第5期403-406,共4页 Chinese Journal of Integrated Traditional and Western Medicine
基金 中国中医科学院创新工程(No.cx-00-07)
关键词 强直性脊柱炎 补肾强脊颗粒 疗效评价 安全性 ankylosing spondylitis Busben Qiangji Granule assessment of efficacy safety
  • 相关文献

参考文献8

  • 1郑筱萸.中药新药临床研究指导原则[M].北京:中国中医药出版社,2001.68.
  • 2Garrett S,Jenkinson T,Whitelock H,et al.A new approach to defining disease status in AS:the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).J Rheumatol 1994; 21 (12):2286-2291.
  • 3Calin A,Garrett S,Whitelock H,et al.A new approach to defining functional ability in ankylosing spondylitis:the development of the Bath Ankylosing Spondylitis Functional Index (BASFI).J Rheumatol 1994;21(12):2281-2285.
  • 4Braun J,Brandt J,Listing J,et al.Treatment of active ankylosing spondylitis with infliximab:a randomized controlled multicentre trial.Lancet 2002;359(9313):1187.
  • 5杨岫岩.强直性脊柱炎的疗效评价[J].实用医学杂志,2002,18(2):118-119. 被引量:11
  • 6Anderson J J,Baron G,van der Heijde D,et al.ASAG preliminary definition of short term improvement in ankylosing spondylitis.Arthritis Rheum 2001 ;44(8):1876-1886.
  • 7Ruof J,Stucki G.Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis:a literature review.J Rheumatol 1999 ;26 (4):966-970.
  • 8施桂英.强直性脊柱炎诊治指南(草案)[J].中华风湿病学杂志,2003,7(10):641-644. 被引量:234

共引文献246

同被引文献188

引证文献12

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部